Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Adrenergic Receptors: β Subtype

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Adrenergic Receptors: ɑ Subtype

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Definition of treatment-resistant late-life depression: Conclusions from a European Task Force Delphi process.

European psychiatry : the journal of the Association of European Psychiatrists·2026

Same author

Unearthing limestone fungal diversity: Description of seven novel species from Portugal.

Fungal systematics and evolution·2025

Same author

The teat skin microbiota of organic primiparous dairy cows is dynamic during the transition period.

Preventive veterinary medicine·2025

Same author

A randomized controlled trial evaluating the efficacy of systemic ceftiofur administration for metritis therapy in dairy cows and the effect of metritis cure on economically important outcomes.

Journal of dairy science·2024

Same author

Exploring associations between the teat apex metagenome and <i>Staphylococcus aureus</i> intramammary infections in primiparous cows under organic directives.

Applied and environmental microbiology·2024

Same author

Dynamics of bla<sub>OXA-23</sub> gene transmission in Acinetobacter spp. from contaminated veterinary environmental surfaces: an emerging One Health threat?

The Journal of hospital infection·2024

Search research articles

Related Experiment Video

Updated: May 20, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

What do we know about the α/β for prostate cancer?

S M Oliveira¹, N J Teixeira, L Fernandes

¹Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Campo Mártires da Pátria, 130, 1169-056 Lisbon, Portugal.

Medical Physics

|July 5, 2012

Summary

The alpha/beta (α/β) ratio for prostate cancer, reflecting radiotherapy sensitivity, is debated. Studies suggest a low α/β value, indicating potential therapeutic gains with larger radiation fractions.

More Related Videos

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

Related Experiment Videos

Last Updated: May 20, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

Area of Science:

Radiation Oncology
Medical Physics
Oncology

Background:

The alpha/beta (α/β) ratio is a key parameter in radiotherapy, determining tissue sensitivity to fractionation.
Prostate cancer's unique biological characteristics, including low labeling indices and long potential doubling times, suggest it may respond like late-responding normal tissues.
Existing research indicates a low α/β value for prostate cancer, estimated around 2.7 Gy.

Purpose of the Study:

To review and synthesize various estimates of the prostate cancer α/β ratio.
To analyze factors influencing these α/β estimations from both clinical and experimental data.
To discuss the implications of a low α/β ratio for radiotherapy treatment planning.

Main Methods:

Literature review of clinical studies evaluating prostate cancer response to different fractionation schedules.
Analysis of experimental data from in vitro and in vivo models investigating prostate cancer radiosensitivity.
Synthesis of findings to identify consensus and discrepancies in α/β ratio estimates.

Main Results:

Multiple studies consistently suggest a low α/β ratio for prostate cancer, generally around 2.7 Gy.
This low α/β value implies that prostate tumors may benefit from hypofractionation (fewer, larger doses).
Variability in estimates is influenced by factors such as treatment protocols, patient populations, and measurement techniques.

Conclusions:

A low α/β ratio for prostate cancer is supported by current evidence, suggesting potential for therapeutic gain.
Hypofractionated radiotherapy regimens may enhance tumor control while sparing surrounding normal tissues.
Further research is needed to refine α/β estimates and optimize treatment strategies for prostate cancer.